Chung-Ang University Hosptial
Seoul, South Korea
NCT Number: NCT07013279
To evaluate the efficacy and safety of DWP712 Inj. in Subjects with Moderate to Severe Glabellar Lines
Trial opening soon.
Get Notified19 year–65 year
All sexes
Interventional
Phase 3
Seoul, South Korea
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Clostridium botulinum Toxin
Clostridium botulinum Toxin
Time frame: At 4 weeks after IP administration
Improvement means FWS grade of "0" or "1" with a ≥2-point improvement from baseline
Daewoong Pharmaceutical Co. LTD.
Industry
A Double-blind, Randomized, Active-controlled, Multi-center, Phase III Study to Evaluate the Efficacy and Safety of DWP712 Inj. in Subjects With Moderate to Severe Glabellar Lines
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06308198
Glabellar Lines
Beijing, Beijing Municipality, China
View Trial DetailsNCT05496335
Glabellar Lines
Newport Beach, California, United States
View Trial DetailsNCT07622004
Glabellar Lines
Seoul, South Korea
View Trial DetailsNCT07398755
Glabellar Lines, Midface Volume Deficiency
Vienna, State of Vienna, Austria
View Trial Details